Sickle erythrocytes' (SSRBCs) unique physical adaptation to hypoxic conditions renders them able to home to hypoxic tumor niches in vivo, shut down tumor blood flow and induce tumoricidal responses. SSRBCs are also useful vehicles for transport of encapsulated drugs and oncolytic virus into hypoxic tumors with enhanced anti-tumor effects. In search of additional modes for arming sickle cells with cytotoxics, we turned to a lentiviral b-globin vector with optimized Locus Control Region/b-globin coding region/promoter/enhancers. We partially replaced the b-globin coding region of this vector with genes encoding T cell cytolytics, perforin and granzyme or immune modulating superantigens SEG and SEI. These modified vectors efficiently transduced Sca Our previous studies sought to arm the SSRBCs with cytotoxics that could be directed to the tumor to enhance their tumoricidal effect.
| I N T R O D U C T I O N
The formation and persistence of hypoxic niches within solid tumors constitutes a major cause of treatment resistance, defective drug transport, and aggressive malignant progression. [1] [2] [3] [4] While many tumor targeting agents have been developed, ranging from small molecules to antibodies and nanoparticles, once administered into the circulation only minute fractions actually reach hypoxic tumor niches largely due to restrictions imposed by endothelial cells, aberrant rheology and other in vivo barriers. [5] [6] [7] This has prompted a search for therapeutics that can target hypoxic tumor niches and deliver a tumoricidal payload.
For this important task we turned to the sickle erythrocyte. This cell is unique in mammals because under conditions extant in the hypoxic recesses of solid tumors sickle hemoglobin (HbS) polymerizes and multiple surface adhesion receptors are upregulated. 8 Intravital microscopy of tumors growing in the dorsal skin window indicates that transfused human sickle erythrocytes' (SSRBCs) rapidly target hypoxic tumor niches, shut down tumor blood flow and produce anti-tumor responses. 8 A clonogenic tumor cytotoxicity assay confirmed a potent synergy between HbS-derived heme and endogenous pro-oxidants in tumor cell eradication. 8 Our previous studies sought to arm the SSRBCs with cytotoxics that could be directed to the tumor to enhance their tumoricidal effect.
To this end, we showed that cytotoxic drugs could be physically encapsulated in SSRBCs and programed ex vivo to discharge 4 times more drug cargo into hypoxic tumors relative to normal RBCs and free drug. 9 Likewise, SSRBCs loaded with oncolytic reovirus directed the virus to melanoma in vivo and exhibited increased tumoricidal effectiveness relative to similarly treated normal RBCs and free virus. 10 While osmosisbased encapsulation allows the entrapment of large quantities of biologics it also injures cell membranes and alters the circulatory kinetics of the modified RBCs. Physical entrapment is confined to a limited group of agents and release at the targeted site can be unpredict- In the current study, we replaced the first exon, first intron and part of the second exon of the beta-globin transgene in the lentiviral vector with genes encoding several biologics including staphylococcal superantigens SEG/SEI and granzyme/perforin. The former are powerful T cell stimulants that have been implicated in anti-tumor effects versus advanced non-small cell lung cancer while the latter are the major cytotoxics used by T cells to generate tumor cytolytic effects. [23] [24] [25] [26] [27] [28] We hypothesized that the powerful b-globin LCR and 
| Vector production
Vectors were produced by transient transfection into 293T cells as previously described 29 with the following modifications. A total of 2.5 3 
| Introduction of granzyme/perforin and SEG/SEI into the b-globin lentiviral vector
Construction of the polycistronic genes construct using PTV1 2A sequences and fusion PCR was performed essentially as described 30 (Supporting Information Figure S1 ). Briefly, mouse Adrb2 cDNA (Clone 1349283; Thermo Scientific) was PCR amplified and modified with primers Adrb2-F and Adrb2-R to contain a 50 bp homology to human 
| Stem cell transduction and transplantation
For stem cell transplantation studies in mice bone marrows from SS mice are isolated from the femurs and tibias and ckit were kept in autoclaved cages, with 1.1 g neomycin sulfate/liter (Sigma N6386) in the drinking water for 2 weeks, after which sterile drinking water was used. They were used after a 3 month rest period to allow for full reconstitution.
| FACS analysis, hemoglobin electrophoresis
Fifty microliters of whole blood were washed in 500 lL PBS. Cell pellets were resuspended in 100 lL lysis solution (5 mM sodium phosphate, 0.5 mM EDTA, pH 7.4) and incubated on ice for 15 minutes.
One tenth volume of 10% NaCl was added and the sample was centrifuged at maximum speed in an Eppendorf microfuge (Hamburg, Germany 
| RT-PCR and western analysis

| RBC lysates and functional testing of superantigen transgenes
Lysates of peripheral blood erythrocytes from C57BL/6 mice reconsti- Cyanine5.5 (SK3; TONBO Biosciences), aCD8 PE (OKT8; TONBO Biosciences).
| Toxic shock model
We used a variant of the toxic shock model described by Miethke 
| Statistics
We deployed the one-wayANOVA with a Tukey's multiple comparison post test for statistical analysis of studies depicted in Figure 4A . SEG and SEI are staphylococcal enterotoxins originating from the enterotoxin gene cluster and display the typical hallmarks of superantigens such as potent TCR vb-specific T cell mitogenicity/activation. 23, 25 It appears that these highly immunogenic and demonstrably mitogenic superantigens are broadly expressed in host SSRBCs for 10 months after transplantation without evoking acute or chronic superantigeninduced toxicity. 31, 32 Indeed, these mice appeared to be immunologically unresponsive to or tolerant of the heterologous superantigen cargo. This tolerance was broken by exposure of the mature SSRBCs to normal murine T cells in vivo. 30 Such tolerance to SEG and SEI in reconstituted mice is likely to have occurred during early hematopoietic reconstitution. Indeed, similar HSC-mediated tolerance to other proteins has been observed in the course of stem cell transplantation. can be programed to occur in the tumor microvessels using ex vivo time dependent photooxidation carried out before administration of the SSRBCs to the patient. 9 Alternatively, the cargo from the SSRBC or its precursors may be released by linking transgene synthesis to a host vesicular transport system that is activated upon synapse with a target cell. The b-globin lentiviral vector therefore provides a potentially broad and flexible platform for expression and delivery of a wide range of erythroid-based therapeutics.
In conclusion, we show that the b-globin lentiviral vector is capable of arming mature SSRBCs with native and foreign tumoricidal transgenes that are robustly expressed in transplanted hosts without toxicity. Coupled with the inherent ability to target tumors and shut down tumor blood flow, SSRBCs armed with cytotoxics constitute a potentially useful tool to augment their tumoricidal effectiveness.
